The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized, phase III study of carboplatin plus paclitaxel for 8 cycles (CP8) versus carboplatin x 8 cycles plus paclitaxel x 4 cycles (C8P4) in advanced ovarian, fallopian, or primary peritoneal carcinoma.
Aristotelis Bamias
No relevant relationships to disclose
Eleni Timotheadou
No relevant relationships to disclose
Gerasimos Aravantinos
No relevant relationships to disclose
Dimitrios G. Pectasides
No relevant relationships to disclose
Christos A. Papadimitriou
No relevant relationships to disclose
George Klouvas
No relevant relationships to disclose
Ioannis Xanthakis
No relevant relationships to disclose
Anastasia G Eleftheraki
No relevant relationships to disclose
Nikolaos Soupos
No relevant relationships to disclose
Thomas Makatsoris
No relevant relationships to disclose
Alexandros Rodolakis
No relevant relationships to disclose
George Vlachos
No relevant relationships to disclose
George E. Pentheroudakis
No relevant relationships to disclose
Alexandros Papanikolaou
No relevant relationships to disclose
Marinos Tsiatas
No relevant relationships to disclose
Aris Antsaklis
No relevant relationships to disclose
George Fountzilas
No relevant relationships to disclose
Meletios A. Dimopoulos
No relevant relationships to disclose